TC Biopharm to test virus-killing cell therapy on Covid-19 patients

Published on 
February 17, 2021
Investing Women

Motherwell-based biotech company TC BioPharm (TCB) is to begin clinical trials of an experimental therapy designed to kill Covid-19 infected cells. TCB previously used gamma-delta T cells (GDTs) donated from healthy volunteers to treat cancer patients and believes they could boost the immune system of those being treated for Covid. It has now gained regulatory approval.

© Investing Women Angels Limited (Company Number SC462552) is a company incorporated in Scotland under the Companies Acts. Registered Office at 2nd Floor, Elder House, Multrees Walk, Edinburgh, EH1 3DX

menu linkedin facebook pinterest youtube rss twitter instagram facebook-blank rss-blank linkedin-blank pinterest youtube twitter instagram